Jordan JFDA Regulatory System Overview: Single Authority and Authorised Representative Requirements

1. Key takeaways

Regulatory authority over medical devices in Jordan is concentrated in one single body — the Jordan Food and Drug Administration (JFDA). The first conclusion GRZAN draws from its Jordan projects is that there is no “split between drugs and devices” to exploit: registration review, import approval, market surveillance and post-market vigilance form a four-stage closed loop that sits entirely inside JFDA.

The second conclusion is equally critical: foreign manufacturers have no right of direct submission. Jordanian law requires an overseas manufacturer to designate in writing a locally licensed company in Jordan as its authorised representative (AR). Every registration submission, sample delivery, vigilance report and customs clearance document must be handled through the AR’s linked account in the JFDA system. No matter how complete the dossier a company prepares at home, without an AR account the file simply cannot enter the official process.

The third conclusion concerns the legal history: JFDA was established under the Interim Law No. 31 of 2003 and initially reported to the Ministry of Health. After Law No. 41 of 2008 was passed, JFDA acquired legal personality together with financial and administrative autonomy, and was restructured to report directly to the Prime Minister. This legislative history determines JFDA’s independent standing within the Jordanian government structure, and it also explains why JFDA circulars carry immediate executive force once issued.

• One authority: JFDA alone controls registration, import approval, market surveillance and vigilance for medical devices in Jordan.
• No direct access: a foreign manufacturer must appoint a Jordanian licensed AR before any submission becomes possible.
• Institutional independence: Law No. 41 of 2008 gave JFDA legal personality and financial and administrative autonomy.
• Circulars matter: JFDA circulars adjust the regulatory posture faster than statutes and are immediately enforceable.

2. Legal basis

The statutory framework relied upon by JFDA is listed by the Jordanian General Budget Department in its official chapter statement on JFDA, which makes the list a verifiable official source. The core instruments are set out below.

Provision numbers are subject to the Arabic original texts of the Jordanian Official Gazette. Before any formal submission, the GRZAN regulatory team verifies the cited provisions by obtaining the original texts from JFDA through the Jordanian authorised representative.

3. Expert insights

Insight 1: a single authority means compliance costs cannot be segmented and outsourced. In several Middle Eastern markets, device registration and import licensing sit with different bodies, and companies can engage separate agents for each. Jordan places registration, import approval, warehouse premises approval, market surveillance and vigilance intake all under JFDA. Any defect at one stage leaves a trace in the same institution’s files and affects subsequent applications. When GRZAN assesses the risk profile of a Jordan project, the compliance history of the proposed AR is treated as a core due diligence item.

Insight 2: JFDA’s autonomy translates into regulatory responsiveness. Law No. 41 of 2008 granted JFDA financial and administrative independence: it may conclude contracts directly, accept donations and legacies, and appoint the Civil Attorney General to represent it in legal proceedings. This autonomy allows JFDA to adjust its regulatory posture quickly through circulars — Circular No. 54863/1/5, issued on 9 October 2025, is a typical example: Class IIb devices must complete registration and obtain JFDA approval before importation, while implantable devices are exempted. A company’s compliance rhythm in Jordan must therefore track the circulars, not only the statutes.

Insight 3: international benchmarking is a stated direction for JFDA. Under the JFDA first priority agenda for 2025–2027 published by the Jordanian government, JFDA aims to obtain WHO regulatory authority listing and PIC/S and ICH membership, with supporting procedures that include upgrading legislation, equipping laboratories to WHO and PIC/S requirements, and upgrading electronic procedures. The direct implication for manufacturers is that review standards will converge toward international baselines: the weight of reference-country reliance routes based on CE or FDA approvals will continue to rise, and local testing requirements may become stricter.

4. Practical recommendations

• Treat AR selection as a compliance decision, not a commercial one. The AR is the responsible entity recorded in JFDA files, and its compliance record is directly linked to your later applications.
• Build a circular-level tracking mechanism. Jordanian statutes are amended less frequently than circulars; track JFDA circulars as the smallest intelligence unit and review the list quarterly.
• Plan reference-country approvals early. If you intend to develop several Middle Eastern markets at the same time, securing CE or FDA approval first can significantly reduce the documentary burden and review friction in Jordan.
• Keep a single consolidated timeline that joins AR appointment, dossier preparation and circular monitoring, so that no stage of the Jordan loop is left uncovered.

5. Verification checklist

• □ Confirm the submission body is JFDA and that no second competent authority participates in device registration approval
• □ Confirm the foreign manufacturer has designated in writing a licensed AR in Jordan and that the AR holds a linked account in the JFDA system
• □ Review the current list of valid JFDA circulars, focusing on circulars governing device importation and circulation
• □ Check whether the product falls under the pre-registration import requirement for Class IIb devices in Circular No. 54863/1/5 (9 October 2025)
• □ Verify whether the JFDA 2025–2027 priorities have added any testing requirement for the intended product category
• □ Re-verify the cited provision numbers against the Arabic original texts of the Official Gazette

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team manages Jordan Food and Drug Administration (JFDA) registrations, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com